Efficacy, tolerability, and safety of transition from beraprost to selexipag in patients with pulmonary arterial hypertension.
Not Applicable
- Conditions
- Pulmonary arterial hypertension
- Registration Number
- JPRN-UMIN000025176
- Lead Sponsor
- Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who added newly concomitant drugs within last 3 months 2. Patients who is expected to intolerable selexipag 3. Patients who had clinically unstable right heart failure within the last 3 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pulmonary arterial resistance (PVR) at week 24 from baseline
- Secondary Outcome Measures
Name Time Method Other variables at week 24 from baseline (1) Right heart catheterization (PCWP, PAP, RVP, CO/CI) (2) NT-proBNP (3) WHO functional class